drugset / Trial / NCT01808768

Ocular Allergy Treatment Practical Impact Trial

NCT01808768

Phase 4 Unknown 50 enrolled Starx Research Center, LLC
NaSingle-groupOpen-labelTreatment

Summary

To study the impact of alcaftadine in patients treated with other opthalmic ocular agents (or specific topical opthalmic treatment) in an allergy subspecialist outpatient setting.

Timeline

Start
2013-04
Primary completion
2013-10
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Alcaftadine Small molecule 0.25 % Other